Text Size

Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells

This study is currently recruiting participants.
Verified March 2012 by Aichi Gakuin University
Sponsor:
Information provided by (Responsible Party):
Keiko Naruse, Aichi Gakuin University
ClinicalTrials.gov Identifier:
NCT01548274
First received: March 5, 2012
Last updated: NA
Last verified: March 2012
History: No changes posted
  Purpose

The purpose of this study is to evaluate the effects of Sarpogrelate in endothelial progenitor cells of patients with atherosclerosis.


Condition Intervention
Atherosclerosis
 Drug: Sarpogrelate

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells

Resource links provided by NLM:

MedlinePlus related topics: Atherosclerosis
U.S. FDA Resources

Further study details as provided by Aichi Gakuin University:

Primary Outcome Measures:
  • The number and function of endothelial progenitor cells [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: October 2010
Estimated Study Completion Date: October 2012
Estimated Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Sarpogrelate
    Sarpogrelate 300mg/day
Detailed Description:

Endothelial progenitor cells play an important role in vasculogenesis and vascular repair. Sarpogrelate, a inhibitor of HT2A, is used an an anti-platelet drug, however, a direct effect in vascular cells is supposed.

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with atherosclerosis

Exclusion Criteria:

  • Patients with high risk of bleeding
  • Patients with pregnancy
  • Patients with allergic reaction of Salpogrelate
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01548274

Locations
Japan
Aichi-Gakuin University Recruiting
Nagoya, Aichi, Japan, 464-8651
Contact: Keiko Naruse, M.D., Ph.D.     +81-52-759-2111 ext 5369     narusek@dpc.agu.ac.jp    
Sponsors and Collaborators
Aichi Gakuin University
  More Information

No publications provided

Responsible Party: Keiko Naruse, Associate professor, Aichi Gakuin University
ClinicalTrials.gov Identifier: NCT01548274     History of Changes
Other Study ID Numbers: AGU-65
Study First Received: March 5, 2012
Last Updated: March 5, 2012
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Aichi Gakuin University:
endothelial progenitor cells

Additional relevant MeSH terms:
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Sarpogrelate
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
 Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses
Hematologic Agents
Platelet Aggregation Inhibitors
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 16, 2013